StocksMediumUpdated•Originally published 4 November 2026•Updated 5 November 2026•
1 min read
NewAmsterdam Pharma Reports Narrower-Than-Expected Q3 2026 Loss
Key Facts
1NewAmsterdam Pharma reported a quarterly loss of $0.14 per share, significantly narrower than the Zacks Consensus Estimate of a $0.5 loss.
NewAmsterdam Pharma reported a quarterly loss of $0.14 per share for the third quarter of 2026. According to Zacks, the loss was narrower than the consensus estimate of $0.5 per share, while the company generated $19.16M in revenue during the period.
The revenue figure for NewAmsterdam Pharma exceeded analyst expectations by $4.11M. Shares of NAMS closed at $19.9 on November 3, 2026, having traded between a session high of $20.46 and a low of $19.59.